These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 7486904)

  • 1. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients.
    Alangaden GJ; Manavathu EK; Vakulenko SB; Zvonok NM; Lerner SA
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1700-3. PubMed ID: 7486904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.
    Cheng AF; Yew WW; Chan EW; Chin ML; Hui MM; Chan RC
    Antimicrob Agents Chemother; 2004 Feb; 48(2):596-601. PubMed ID: 14742214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.
    Takiff HE; Salazar L; Guerrero C; Philipp W; Huang WM; Kreiswirth B; Cole ST; Jacobs WR; Telenti A
    Antimicrob Agents Chemother; 1994 Apr; 38(4):773-80. PubMed ID: 8031045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones.
    Revel V; Cambau E; Jarlier V; Sougakoff W
    Antimicrob Agents Chemother; 1994 Sep; 38(9):1991-6. PubMed ID: 7811008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro.
    Dessus-Babus S; Bébéar CM; Charron A; Bébéar C; de Barbeyrac B
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2474-81. PubMed ID: 9756744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin.
    Cambau E; Sougakoff W; Besson M; Truffot-Pernot C; Grosset J; Jarlier V
    J Infect Dis; 1994 Aug; 170(2):479-83. PubMed ID: 8035042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.
    Zhu C; Zhang Y; Shen Y; Siu GK; Wu W; Qian X; Deng G; Xu Y; Lau R; Fan X; Zhang W; Lu H; Yam WC
    Diagn Microbiol Infect Dis; 2012 Jul; 73(3):260-3. PubMed ID: 22560167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance.
    Suzuki Y; Nakajima C; Tamaru A; Kim H; Matsuba T; Saito H
    Int J Antimicrob Agents; 2012 May; 39(5):435-9. PubMed ID: 22421328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene.
    Tankovic J; Mahjoubi F; Courvalin P; Duval J; Leclerco R
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2558-61. PubMed ID: 8913464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonradioactive single-strand conformation polymorphism analysis for detection of fluoroquinolone resistance in mycobacteria.
    Sougakoff W; Lemaître N; Cambau E; Szpytma M; Revel V; Jarlier V
    Eur J Clin Microbiol Infect Dis; 1997 May; 16(5):395-8. PubMed ID: 9228484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.
    Ozeki S; Deguchi T; Yasuda M; Nakano M; Kawamura T; Nishino Y; Kawada Y
    J Clin Microbiol; 1997 Sep; 35(9):2315-9. PubMed ID: 9276409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003.
    Huang TS; Kunin CM; Shin-Jung Lee S; Chen YS; Tu HZ; Liu YC
    J Antimicrob Chemother; 2005 Dec; 56(6):1058-62. PubMed ID: 16204341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field.
    Giraud E; Brisabois A; Martel JL; Chaslus-Dancla E
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2131-7. PubMed ID: 10471553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.